Biological markers for the clinical diagnosis of Alzheimer's disease

Hiroyuki Arai

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)


There is a compelling need to develop biological marker(s) to confirm a clinical diagnosis of Alzheimer's disease (AD) during life in order to unequivocally identify AD patients for emerging therapeutic interventions. This review describes recent advances in the development of diagnostic marker(s) for AD, They include polymorphism of apolipoprotein E (ApoE) and α1-antichymotrypsin as well as cerebrospinal fluid (CSF) tau and CSF-amyloid β-protein levels, skin biopsy, and pupil dilatation assay by anti-cholinergic agent. In conclusion, ApoE genotyping should not be used as a sole diagnostic test for AD, and that monitoring of CSF-tau appeared to be most promising and reliable diagnostic aid. - Apolipoprotein E gene; cerebrospinal fluid; tau protein; α1-antichymotrypsin gene; pupil assay; Alzheimer's disease.

Original languageEnglish
Pages (from-to)65-79
Number of pages15
JournalTohoku Journal of Experimental Medicine
Issue number2
Publication statusPublished - 1996 Jun

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Biological markers for the clinical diagnosis of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this